• Cumberland Pharmaceuticals plans to seek FDA approval for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy, which has no specifically approved treatment.
• The FDA granted rolling review, allowing submission of completed application sections before the full filing.
• Reported Phase 2 FIGHT DMD results showed improved heart function with high-dose ifetroban versus controls, with no treatment-related serious adverse events.
• Longer-term heart imaging results are being analyzed for inclusion in the application.
• The FDA suggested a Phase 3 trial, questioned efficacy evidence and requested additional analyses, including on missing data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610261640PR_NEWS_USPR_____CL81369) on October 26, 2026, and is solely responsible for the information contained therein.